Developing as a significant breakthrough in the fight against obesity, this medication is attracting considerable interest . It combines effects of two established GLP-1 receptor agonists, semaglutide , with an new glucose-dependent incretin component. Initial study data have shown substantial body decrease in people with obesity , perhaps pres… Read More